HENDERSON, Nev., Aug. 8, 2007 (PRIME NEWSWIRE) -- BodyTel Scientific, Inc. (OTCBB:BDYT), a company focused on the development of innovative wireless healthcare products, announced the formation of BodyTel North America LLC, a wholly owned subsidiary of BodyTel Scientific, Inc. The new subsidiary will be responsible for sales and marketing within North America for the BodyTel Scientific product pipeline.
With the company currently pursuing the U.S. Food & Drug Administration's (FDA) approval to market its blood glucose monitoring device, GlucoTel, the new subsidiary will be gearing up for the U.S. product launch, which is anticipated towards the end of the year. The subsidiary will be hiring marketing and sales representatives as well as regulatory staff, and technical project managers.
BodyTel Scientific, Inc., President and CEO, Stefan Schraps, commented, "The U.S. market has a large and growing diabetic population, estimated at over 20 million Americans, which would benefit greatly from our innovative and user-friendly glucose monitoring device. Based on the attention the GlucoTel System has been receiving within the U.S. health care industry, we feel now is the right time to begin recruiting qualified sales and administrative personnel for the upcoming launch of GlucoTel, the world's first and only diabetes self-management system with integrated Bluetooth."
BodyTel Scientific's mission is to provide innovative high quality monitoring products and services to the healthcare industry. The initial product release will be the GlucoTel Blood Glucose Meter targeting the growing diabetes industry. This monitoring device is a small and easy to read meter which wirelessly monitors patients with diabetes using Bluetooth(tm) and cellular phone technology. In real-time, data is sent to a secure web site and stored long-term.
About BodyTel Scientific, Inc.
BodyTel Scientific, Inc. is a company focused on the development of innovative wireless health monitoring products. Please visit www.bodytel.com for more company information.
Forward-Looking Statements
Statements regarding the Company's business which are not historical facts are "forward-looking statements" that involve risks and uncertainties that could cause actual results to differ materially from the potential results discussed in the forward-looking statements. Forward-looking statements in this press release include that the new subsidiary will be responsible for sales and marketing within North America, With the company currently pursuing the U.S. Food & Drug Administration's (FDA) approval to market its blood glucose monitoring device, GlucoTel, the new subsidiary will be gearing up for the U.S. product launch which is anticipated towards the end of the year and that The U.S. market has a large and growing diabetic population, which would benefit greatly from our innovative and user-friendly glucose monitoring device. Actual results may differ materially from those currently anticipated due to a number of factors as we may find that our products must compete with cheaper or better products; we may not be able to retain key employees; a bigger market may not develop for our products and we may not be able to continue to attract new customers; we may face litigation if our technology fails to work when required; our intellectual property may be attacked and defeated in court proceedings; our patent and FDA/CE filings may be rejected by the patent offices and regulators; other companies may discover and develop better or cheaper technologies that would render our products obsolete and we may not have sufficient funding to further develop and/or market our technology. Readers are directed to the BodyTel Scientific, Inc.'s reports as filed with the U.S. Securities and Exchange Commission from time to time, including but not limited to its 8-K filed December 14, 2006 under our prior name Sellcell.net which outlined the company's current business for further information and factors that may affect BodyTel Scientific Inc.'s business and results of operations as well as the Company's form 10-KSB filed on December 15, 2006 and the Company's form 10-QSB filed on January 16, 2007. BodyTel Scientific Inc. undertakes no obligations to publicly update any forward-looking statements to reflect future events or circumstances.